Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sinopharm Group CoSHTDF -6.74%78 Shiller PE Ratio is 5.93 as of Jul. 22, 2026, which is 44% below its 10-year median of 10.65. GuruFocus rates SHTDF with a GF Score™ of 78/100 and a GF Value™ of $2.60 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 66 Medical Distribution companies, Sinopharm Group Co ranks better than 90.91% on this metric.
The historical rank and industry rank for Sinopharm Group Co's Shiller PE Ratio or its related term are showing as below:
SHTDF'
s Shiller PE Ratio Range Over the Past 10 Years
Min: 5.91 Med: 10.65 Max: 49.94
Current: 6.45
During the past 13 years, Sinopharm Group Co's highest Shiller PE Ratio was 49.94. The lowest was 5.91. And the median was 10.65.
SHTDF's Shiller PE Ratio is ranked better than 90.91% of 66
companies
in the Medical Distribution industry
Industry Median: 14.94
vs SHTDF: 6.45
E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.
Sinopharm Group Co's adjusted earnings per share data of for the fiscal year that ended in Dec25 was $0.325. Add all the adjusted EPS for the past 10 years together and divide 10 will get our E10, which is $0.36 for the trailing ten years ended in Dec25.
Shiller PE for Stocks: The True Measure of Stock Valuation
Sinopharm Group Co (OTCPK:SHTDF) Shiller PE Ratio Explanation
Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.
Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.
Be Aware
Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.
Sinopharm Group Co Shiller PE Ratio Related Terms
Sinopharm Group Co Shiller PE Ratio Historical Data
* Premium members only.
The historical data trend for Sinopharm Group Co's Shiller PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHTDF vs MCK, CAH, COR: Shiller PE Ratio Comparison
For the Medical Distribution subindustry, Sinopharm Group Co's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sinopharm Group Co Shiller PE Ratio vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Sinopharm Group Co's Shiller PE Ratio distribution charts can be found below:
* The bar in red indicates where Sinopharm Group Co's Shiller PE Ratio falls into.
For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Add all the adjusted EPS together and divide 10 will get our E10.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
Sinopharm Group Co (SHTDF) has a Shiller PE Ratio of 5.93 as of Jul. 22, 2026. Shiller price-earnings ratio is the ratio of share price to a company's inflation-adjusted earnings over a 10-year period. View historical data on Sinopharm Group Co and its competitors. This is 44% below median its historical median of 10.65. Over the past decade, Sinopharm Group Co's Shiller PE Ratio has ranged from 5.91 to 49.94. According to the industry distribution chart, Sinopharm Group Co ranks #6 out of 66 companies in the Medical Distribution industry, placing it in the top 9.1%.
Is Sinopharm Group Co's Shiller PE Ratio too high?
Sinopharm Group Co's current Shiller PE Ratio of 5.93 is 44% below median its 10-year median of 10.65. Over the past 10 years, this metric has ranged from a low of 5.91 to a high of 49.94. The Medical Distribution industry median Shiller PE Ratio is 14.94. Sinopharm Group Co's value of 5.93 is 60.3% below this industry median. Based on the distribution chart, Sinopharm Group Co ranks #6 out of 66 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, Sinopharm Group Co has a GF Score™ of 78/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sinopharm Group Co's Shiller PE Ratio compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Sinopharm Group Co ranks #6 out of 66 companies for Shiller PE Ratio. This places Sinopharm Group Co in the top 9% of its industry — outperforming the majority of peers. The industry median Shiller PE Ratio is 14.94. Sinopharm Group Co's value of 5.93 is 60.3% below this benchmark. Historically, Sinopharm Group Co's own Shiller PE Ratio has ranged from 5.91 to 49.94 over the past decade. While the company's 10-year median is 10.65 vs. the industry median of 14.94, Sinopharm Group Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shiller PE Ratio for a Medical Distribution company?
The median Shiller PE Ratio among Medical Distribution companies is 14.94, based on 66 companies in the industry. Companies in the top quartile (top 25%) have a Shiller PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Shiller PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sinopharm Group Co's current Shiller PE Ratio of 5.93 is 60.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shiller PE Ratio mean?
A high Shiller PE Ratio can signal that a stock is expensive relative to its fundamentals. Shiller price-earnings ratio is the ratio of share price to a company's inflation-adjusted earnings over a 10-year period. View historical data on Sinopharm Group Co and its competitors. For the Medical Distribution industry, the median Shiller PE Ratio is 14.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sinopharm Group Co's current Shiller PE Ratio is 5.93, which is 44% below median its own 10-year median of 10.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sinopharm Group Co stock overvalued right now?
Based on GuruFocus' analysis, Sinopharm Group Co (SHTDF) is currently considered Modestly Undervalued. The stock's GF Value™ is $2.60, compared to a current price of $2.13 — trading 18% below its estimated fair value. The current Shiller PE Ratio is 5.93, which is 44% below median its 10-year median of 10.65 and 60.3% below the Medical Distribution industry median of 14.94. Sinopharm Group Co's overall GF Score™ is 78/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shiller PE Ratio calculated?
Shiller PE Ratio is calculated from a company's financial statements. For Sinopharm Group Co (SHTDF), the current Shiller PE Ratio is 5.93 as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sinopharm Group Co (SHTDF) Overvalued in 2026?
Based on GuruFocus' analysis, Sinopharm Group Co stock appears to be undervalued.
The current stock price of $2.13 is trading 18% below its estimated GF Value™ of $2.60.
GuruFocus considers Sinopharm Group Co to be Modestly Undervalued.
Key valuation signals for SHTDF:
Shiller PE Ratio: 5.93 (44% below median its 10-year median of 10.65)
GF Value™: $2.60 vs. price of $2.13 (18% below fair value)
Industry Position: 60.3% below the Medical Distribution median (#6 of 66)
No single metric tells the full story. See the SHTDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Founded in 2003, Sinopharm is the largest wholesaler and retailer of drugs and medical devices in China and listed on the Hong Kong Stock Exchange in 2009. It is a core subsidiary of China National Pharmaceutical Group. Sinopharm's largest operating segment is pharmaceutical distribution, making up over 70% of its total revenue by the end of 2024. In 2018, Sinopharm acquired the largest Chinese medical device distributor, China National Scientific Instruments and Materials. Now, medical device distribution accounts for over 20% of Sinopharm's total revenue. Sinopharm's downstream customers range from hospitals and other health services institutions to end-customers.
78GF Score
Get the complete analysis for SHTDF
Shiller PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHTDF has been successfully added to your 
